Published in Ann Oncol on June 01, 2001
Cell signaling by receptor tyrosine kinases. Cell (2010) 12.39
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev (2008) 2.61
Proteomic and immunologic analyses of brain tumor exosomes. FASEB J (2008) 2.11
Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A (2009) 2.11
The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia (2009) 1.64
Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther (2009) 1.55
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.45
The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med (2007) 1.37
Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene (2010) 1.30
Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem (2009) 1.28
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays (2007) 1.26
Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer (2008) 1.24
Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging (2007) 1.23
The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer (2008) 1.15
Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia (2011) 1.07
Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling. PLoS Comput Biol (2013) 1.06
Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer (2005) 0.99
Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther (2008) 0.99
Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation. Cancers (Basel) (2011) 0.98
Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci U S A (2005) 0.98
HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J (2012) 0.94
EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins. Oncogene (2006) 0.93
Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol (2007) 0.91
Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. Protein Eng Des Sel (2011) 0.91
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). J Clin Pathol (2006) 0.89
The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. J Neurooncol (2010) 0.87
Hypermethylated Epidermal growth factor receptor (EGFR) promoter is associated with gastric cancer. Sci Rep (2015) 0.87
EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma. Oncogene (2013) 0.86
A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors. Oncogene (2011) 0.86
Met interacts with EGFR and Ron in canine osteosarcoma. Vet Comp Oncol (2011) 0.86
Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer. Cancer Invest (2010) 0.84
Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. J Med Genet (2006) 0.84
Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization. J Cell Mol Med (2009) 0.84
The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Neoplasia (2012) 0.83
A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors. Cancer Biol Ther (2013) 0.82
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer. PLoS One (2013) 0.82
Cancer metastasis and EGFR signaling is suppressed by amiodarone-induced versican V2. Oncotarget (2015) 0.81
Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. Onco Targets Ther (2013) 0.81
The novel gene tank, a tumor suppressor homolog, regulates ethanol sensitivity in Drosophila. J Neurosci (2013) 0.79
EGFRvIII mediates hepatocellular carcinoma cell invasion by promoting S100 calcium binding protein A11 expression. PLoS One (2013) 0.79
Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells. Cancer Biol Ther (2015) 0.78
A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma. Mol Cancer Res (2016) 0.78
Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity. J Exp Clin Cancer Res (2013) 0.78
Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol (2017) 0.78
Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer. Biologics (2007) 0.77
Organ Specific Tumor Markers: What's New? Indian J Clin Biochem (2011) 0.77
Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC). Sultan Qaboos Univ Med J (2013) 0.76
Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung. Thorac Cancer (2015) 0.76
Generation of fusion protein EGFRvIII-HBcAg and its anti-tumor effect in vivo. J Exp Clin Cancer Res (2009) 0.76
Simultaneous in vivo fluorescent markers for perfusion, protoporphyrin metabolism and EGFR expression for optically guided identification of orthotopic glioma. Clin Cancer Res (2016) 0.75
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev (2016) 0.75
New anti-cancer chemicals Ertredin and its derivatives, regulate oxidative phosphorylation and glycolysis and suppress sphere formation in vitro and tumor growth in EGFRvIII-transformed cells. BMC Cancer (2016) 0.75
Is membranous location of EGFR or EGFRvIII immunostaining associated with good prognosis in renal cell carcinoma? Br J Cancer (2005) 0.75
EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery. Receptors Clin Investig (2016) 0.75
EGFR Family Members' Regulation of Autophagy Is at a Crossroads of Cell Survival and Death in Cancer. Cancers (Basel) (2017) 0.75
Low Incidence along with Low mRNA Levels of EGFR(vIII) in Prostate and Colorectal Cancers Compared to Glioblastoma. J Cancer (2017) 0.75
Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A (1997) 2.12
Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol (1997) 1.61
Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene (2010) 1.52
Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. Eur J Cancer Clin Oncol (1988) 1.45
Auto- and cross-induction within the mammalian epidermal growth factor-related peptide family. J Biol Chem (1994) 1.40
Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci U S A (1997) 1.23
The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer (1990) 1.02
Semiquantitative oestrogen receptor assay in formalin-fixed paraffin sections of human breast cancer tissue using monoclonal antibodies. Br J Cancer (1986) 1.02
Human breast cancer: heterogeneity of estrogen binding sites. Cancer (1981) 1.00
Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer (2005) 0.99
Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Br J Cancer (1999) 0.99
Immunohistochemical demonstration of estrogen receptors (ER) in formalin-fixed, paraffin-embedded human breast cancer tissue by use of a monoclonal antibody to ER. J Histochem Cytochem (1988) 0.97
Oestrogen receptor assay--limitation of the method. Eur J Cancer (1981) 0.97
Estrogen receptor content and ploidy of human mammary carcinoma. Cancer (1982) 0.95
Prognostic factors in osteosarcomas. A regression analysis. Cancer (1988) 0.91
The use of monoclonal antibodies to estrogen receptors (ER) for immunoperoxidase detection of ER in paraffin sections of human breast cancer tissue. J Histochem Cytochem (1985) 0.91
The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer. Cancer Gene Ther (2006) 0.90
Needs for everyday life support for brain tumour patients' relatives: systematic literature review. Eur J Cancer Care (Engl) (2011) 0.89
A population-based study of thyroid function after radiotherapy and chemotherapy for a childhood brain tumor. J Clin Endocrinol Metab (2003) 0.89
Growth suppression by transforming growth factor beta 1 of human small-cell lung cancer cell lines is associated with expression of the type II receptor. Br J Cancer (1994) 0.88
Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. An immunohistochemical study in human breast cancer. Acta Oncol (1988) 0.88
Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res (1992) 0.87
Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer (1989) 0.85
Oestrogen-receptor determinations on fine-needle aspirations from malignant tumours of the breast. Eur J Cancer (1979) 0.85
Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res (1999) 0.84
A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. Cancer Gene Ther (2008) 0.84
Assessment of the hypothalamo-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumor. J Clin Endocrinol Metab (2003) 0.84
Transforming growth factor beta and cancer. Cancer Treat Rev (1995) 0.84
Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor. Cancer Gene Ther (2000) 0.83
Gynecomastia. Immunohistochemical demonstration of estrogen receptors. Acta Pathol Microbiol Immunol Scand A (1987) 0.83
Profile of differentially expressed genes mediated by the type III epidermal growth factor receptor mutation expressed in a small-cell lung cancer cell line. Br J Cancer (2001) 0.83
Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. J Neurooncol (1999) 0.83
Cranial radiotherapy of childhood brain tumours: growth hormone deficiency and its relation to the biological effective dose of irradiation in a large population based study. Clin Endocrinol (Oxf) (2000) 0.83
Immunohistochemical analysis of estrogen receptors (ER) using formalin-fixed paraffin-embedded breast cancer tissue: correlation with clinical endocrine response. J Steroid Biochem (1988) 0.82
Ploidy level of human breast carcinoma. Relation to histopathologic features and hormone receptor content. Acta Radiol Oncol (1984) 0.82
Characterization of the T61 human breast carcinoma established in nude mice. Eur J Cancer Clin Oncol (1985) 0.82
Estrogen receptors in human breast cancer: comparative features of the hydroxylapatite- and dextran-coated charcoal assay. Eur J Cancer Clin Oncol (1982) 0.82
Transforming growth factor-alpha. Baillieres Clin Gastroenterol (1996) 0.81
[Sarcoma treatment in Denmark]. Ugeskr Laeger (1990) 0.81
Gonadal status in male survivors following childhood brain tumors. J Clin Endocrinol Metab (2001) 0.81
Review of the curative role of radiotherapy in the treatment of non-small cell lung cancer. Lung Cancer (1994) 0.81
Growth hormone response to a growth hormone-releasing hormone stimulation test in a population-based study following cranial irradiation of childhood brain tumors. Horm Res (2000) 0.80
Expression and autoregulation of transforming growth factor beta receptor mRNA in small-cell lung cancer cell lines. Br J Cancer (1996) 0.80
Preparation and purification of cationic solid lipid nanospheres--effects on particle size, physical stability and cell toxicity. Int J Pharm (2003) 0.80
Glucocorticoid receptors in human malignancies: a review. Ann Oncol (1991) 0.80
Absence of association between oestrogen-receptor content and in vitro oestrogen sensitivity in human breast cancer. Acta Pathol Microbiol Scand A (1978) 0.80
Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line. Int J Cancer (2001) 0.79
Effect of hyperthermia and environmental acidity on the proteolytic activity in murine ascites tumor cells. J Natl Cancer Inst (1977) 0.79
Glucose-6-phosphate dehydrogenase activity in human breast cancer. Lack of association with oestrogen receptor content. Acta Pathol Microbiol Scand A (1981) 0.79
Oestrogen receptors in human breast cancer. Problems of correlation with histopathological features. Virchows Arch A Pathol Anat Histol (1982) 0.78
Immunoreactive opioid peptides in human breast cancer. Am J Pathol (1989) 0.78
Insertion of a nuclear factor kappa B DNA nuclear-targeting sequence potentiates suicide gene therapy efficacy in lung cancer cell lines. Cancer Gene Ther (2012) 0.77
The dynamic expression of the epidermal growth factor receptor and epidermal growth factor ligand family in a differentiating intestinal epithelial cell line. Growth Factors (1999) 0.77
Cellular radiosensitivity of small-cell lung cancer cell lines. Int J Radiat Oncol Biol Phys (1997) 0.77
Dosimetry and growth hormone deficiency following cranial irradiation of childhood brain tumors. Med Pediatr Oncol (1999) 0.77
Retroperitoneal fibrosis after long-term daily use of ergotamine. Int Urol Nephrol (1986) 0.76
A prospective PET study of patients with glioblastoma multiforme. Acta Neurol Scand (2006) 0.76
Comparative immunoperoxidase demonstration of T-antigens in human colorectal carcinomas and morphologically abnormal mucosa. Cancer Res (1985) 0.76
Immunocytochemical determination of the estrogen-regulated protein Mr 24,000 in primary breast cancer and response to endocrine therapy. Eur J Cancer Clin Oncol (1989) 0.76
High value of the radiobiological parameter Dq correlates to expression of the transforming growth factor beta type II receptor in a panel of small cell lung cancer cell lines. Lung Cancer (1998) 0.75
Metabolic and hemodynamic evaluation of brain metastases from small cell lung cancer with positron emission tomography. Clin Cancer Res (1998) 0.75
Short-term culture of human breast cancer: in vitro effects of hormones related to patient response. Br J Cancer (1982) 0.75
Leukotriene B4 receptor levels and intracellular calcium signalling in polymorphonuclear leukocytes from patients with Crohn's disease. Eur J Gastroenterol Hepatol (1995) 0.75
Quality control of receptor analyses of breast cancer tissue in Denmark. Acta Oncol (1988) 0.75
Hepatic cytosolic oestrogen receptors in patients with liver disease. J Intern Med (1993) 0.75
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. J Immunol Methods (1997) 0.75
Impact of standardization of estrogen and progesterone receptor assays of breast cancer biopsies in Denmark. Eur J Cancer Clin Oncol (1988) 0.75
Expression of cell cycle regulating factor mRNA in small cell lung cancer xenografts. Folia Microbiol (Praha) (1998) 0.75
Quality control of estrogen and progesterone receptor analyses in Denmark. Recent Results Cancer Res (1984) 0.75
Gene therapy for lung cancer. Lung Cancer (1999) 0.75
[Estrogen receptor determination in malignant breast tumor tissue. How can false negative results be avoided?]. Ugeskr Laeger (1981) 0.75
Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13-17, 1996, Ermatingen, Switzerland. Ann Oncol (1997) 0.75
[Synovial sarcoma]. Ugeskr Laeger (1989) 0.75
Relation between mammographic findings and hormonal receptor content in breast cancer. AJR Am J Roentgenol (1985) 0.75
Variation in hepatic estrogen receptor concentrations in patients with liver disease. A multivariate analysis. Scand J Gastroenterol (1992) 0.75
5th I.A.S.L.C. Lung Tumor Biology Workshop, August 13-17, 1996, Ermatingen, Switzerland. Lung Cancer (1997) 0.75
Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated charcoal assay. Acta Oncol (1991) 0.75
Formaldehyde-fluorescamine-induced fluorescence of mammary carcinoma cells. Lack of concordance with occurrence of oestrogen-binding receptor proteins. Virchows Arch B Cell Pathol Incl Mol Pathol (1979) 0.75
Enzyme immunoassay of oestrogen receptors in needle biopsies from human liver. Liver (1991) 0.75
A prospective study of circulating immune complexes in patients with breast cancer. Int J Cancer (1988) 0.75
Basic actions of transforming growth factor-alpha and related peptides. Eur J Gastroenterol Hepatol (1995) 0.75
[Transforming growth factor beta. A potent multifunctional growth factor for normal and malignant cells]. Ugeskr Laeger (1992) 0.75
Small cell lung cancer: biological and therapeutic aspects. Crit Rev Oncol Hematol (1996) 0.75
Bone mineral content and estrogen receptors in patients with breast cancer. Eur J Cancer (1979) 0.75
Prediction of hormone responsiveness by mammographic parenchymal pattern in advanced primary breast cancer. Breast Cancer Res Treat (1992) 0.75
Oestrogen receptor assay. False positive analysis? Acta Radiol Oncol (1984) 0.75
DNA profile and steroid receptor content of human ovarian cancer. Eur J Gynaecol Oncol (1988) 0.75
Demonstration of hormonal sensitivity in gynaecomastic tissue by thymidine incorporation in vitro. Acta Pathol Microbiol Scand A (1977) 0.75
Acquired TGF beta 1 sensitivity and TGF beta 1 expression in cell lines established from a single small cell lung cancer patient during clinical progression. Lung Cancer (1996) 0.75
Gynecomasty: estrogen and androgen receptors. A clinical-pathological investigation. Acta Pathol Microbiol Immunol Scand A (1985) 0.75
Extra-visceral soft tissue sarcomas in adults: local treatment with special reference to irradiation. Cancer Treat Rev (1989) 0.75